NO965591L - Kombinasjonsbehandling av HIV-infeksjon - Google Patents
Kombinasjonsbehandling av HIV-infeksjonInfo
- Publication number
- NO965591L NO965591L NO965591A NO965591A NO965591L NO 965591 L NO965591 L NO 965591L NO 965591 A NO965591 A NO 965591A NO 965591 A NO965591 A NO 965591A NO 965591 L NO965591 L NO 965591L
- Authority
- NO
- Norway
- Prior art keywords
- hiv infection
- hiv
- combination treatment
- treatment
- combination
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title abstract 3
- 208000037357 HIV infectious disease Diseases 0.000 title abstract 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title abstract 3
- 238000011284 combination treatment Methods 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010010369 HIV Protease Proteins 0.000 abstract 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract 1
- 229940122440 HIV protease inhibitor Drugs 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000004030 hiv protease inhibitor Substances 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical class CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 abstract 1
- 229960000689 nevirapine Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Blandingen av HIV-protease-inhibitoren, forbindelse J, og ett eller flere av nevarapin og et a-APA-derivat kan anvendes ved inhiberingen av HIV-protease, inhiberingen av HIV-reverstranskriptase, forhindringen eller behandlingen av infeksjon med HIV og behandlingen av AIDS, enten som for-bindelser, farmasøytisk akseptable sal-ter, bestanddeler i farmasøytisk pre-parat, enten i kombinasjon med eller ikke i kombinasjon med andre antivirus-midler, immunmodulatorer, antibiotika eller vaksiner. Fremgangsmåter for behandling av AIDS og fremgangsmåter for forhindring eller behandling av infeksjon med HIV er også beskrevet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26708594A | 1994-06-27 | 1994-06-27 | |
| PCT/US1995/007690 WO1996000068A2 (en) | 1994-06-27 | 1995-06-23 | Combination therapy for hiv infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO965591L true NO965591L (no) | 1996-12-27 |
| NO965591D0 NO965591D0 (no) | 1996-12-27 |
Family
ID=23017251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO965591A NO965591D0 (no) | 1994-06-27 | 1996-12-27 | Kombinasjonsbehandling av HIV-infeksjon |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0767664A2 (no) |
| JP (1) | JPH10503178A (no) |
| AU (1) | AU2863895A (no) |
| CA (1) | CA2193221A1 (no) |
| CZ (1) | CZ375196A3 (no) |
| FI (1) | FI965196A (no) |
| HU (1) | HUT76546A (no) |
| IL (1) | IL114208A0 (no) |
| MX (1) | MX9700036A (no) |
| NO (1) | NO965591D0 (no) |
| PL (1) | PL317876A1 (no) |
| SK (1) | SK163996A3 (no) |
| WO (1) | WO1996000068A2 (no) |
| ZA (1) | ZA955269B (no) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6689761B1 (en) | 1995-02-01 | 2004-02-10 | Merck & Co., Inc. | Combination therapy for HIV infection |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| EP0872233A1 (en) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
| GB2324242A (en) * | 1997-04-18 | 1998-10-21 | Atindra Nath Chakrabarty | Medicaments for treating viral infections |
| AU775360B2 (en) | 1999-09-24 | 2004-07-29 | Janssen Pharmaceutica N.V. | Antiviral compositions |
| EP4215900A1 (en) | 2015-09-23 | 2023-07-26 | Malvern Panalytical Limited | Particle characterisation |
-
1995
- 1995-06-19 IL IL11420895A patent/IL114208A0/xx unknown
- 1995-06-23 JP JP8503245A patent/JPH10503178A/ja active Pending
- 1995-06-23 CA CA002193221A patent/CA2193221A1/en not_active Abandoned
- 1995-06-23 CZ CZ963751A patent/CZ375196A3/cs unknown
- 1995-06-23 EP EP95923935A patent/EP0767664A2/en not_active Withdrawn
- 1995-06-23 WO PCT/US1995/007690 patent/WO1996000068A2/en not_active Application Discontinuation
- 1995-06-23 HU HU9603567A patent/HUT76546A/hu unknown
- 1995-06-23 AU AU28638/95A patent/AU2863895A/en not_active Withdrawn
- 1995-06-23 MX MX9700036A patent/MX9700036A/es unknown
- 1995-06-23 PL PL95317876A patent/PL317876A1/xx unknown
- 1995-06-23 SK SK1639-96A patent/SK163996A3/sk unknown
- 1995-06-26 ZA ZA955269A patent/ZA955269B/xx unknown
-
1996
- 1996-12-23 FI FI965196A patent/FI965196A/fi not_active Application Discontinuation
- 1996-12-27 NO NO965591A patent/NO965591D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI965196A0 (fi) | 1996-12-23 |
| CZ375196A3 (en) | 1997-07-16 |
| HUT76546A (en) | 1997-09-29 |
| FI965196A (fi) | 1996-12-23 |
| PL317876A1 (en) | 1997-04-28 |
| HU9603567D0 (en) | 1997-02-28 |
| CA2193221A1 (en) | 1996-01-04 |
| JPH10503178A (ja) | 1998-03-24 |
| AU2863895A (en) | 1996-01-19 |
| SK163996A3 (en) | 1997-08-06 |
| IL114208A0 (en) | 1995-10-31 |
| EP0767664A2 (en) | 1997-04-16 |
| ZA955269B (en) | 1996-02-02 |
| NO965591D0 (no) | 1996-12-27 |
| MX9700036A (es) | 1997-04-30 |
| WO1996000068A3 (en) | 1996-02-22 |
| WO1996000068A2 (en) | 1996-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60036961D1 (de) | Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer | |
| DE69228106T2 (de) | HIV-Protease-Inhibitoren | |
| NO953308L (no) | Inhibitorer av HIV-reverstranskriptase | |
| MY109834A (en) | Benzoxazinones as inhibitors of hiv reverse transcriptase | |
| DE69531944D1 (de) | Neue hiv-protease-inhibitoren | |
| ATE215952T1 (de) | Hiv-proteaseinhibitoren | |
| NO962000L (no) | Prolegemidler av en inhibitor av HIV-protease | |
| ZA991029B (en) | Composition and methods for treatment of hiv infections. | |
| NO965591L (no) | Kombinasjonsbehandling av HIV-infeksjon | |
| EA199700150A1 (ru) | КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC | |
| NO20002481L (no) | Kombinasjonsterapi for behandling av AIDS | |
| DE69529678T2 (de) | Kombinationen von hiv-protease inhibitoren | |
| NO944208L (no) | Nye kinazoliner som inhibitorer av HIV-reverstranskriptase |